Antidepressant Use Trajectories and Risk of Discontinuation After Adolescents and Young Adult Cancer Diagnosis
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Oluwadamilola Onasanya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antidepressive Agents, Neoplasms, Depression. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Institute for Clinical and Translational Research, University of Maryland, Baltimore.
Abstract (Originalsprache)
Background
Little is known about the continuity of antidepressant treatment after adolescent and young adult (AYA) cancer diagnosis. Clinical guidelines recommend that past antidepressant use trajectories should inform decisions on discontinuation after cancer diagnosis. We characterized AYAs' antidepressant adherence trajectories before incident cancer diagnosis and assessed any association between their past adherence trajectory and the risk of antidepressant discontinuation up to 1 year afterward.
Methods
We conducted a retrospective, longitudinal cohort study of AYAs receiving ≥ 2 antidepressant fills 9 months before incident cancer diagnosis (index date). Group‐based trajectory modeling was used to estimate latent subgroups of antidepressant adherence before cancer diagnosis, using monthly proportions of days covered (PDC) over the nine‐month baseline; IQVIA PharMetrics Plus for Academics US claims, 2006–2020. Discontinuation was defined as ≥ 60‐days gap without antidepressants within 1 year post‐index date.
Results
We observed three distinct antidepressant adherence trajectory groups before cancer diagnosis: recent start (17% of cohort, mean PDC [range]: 0.25 [0.03–0.49]); gradually increasing (36%, mean PDC [range]: 0.57 [0.22–0.81]); and consistently high (47%, mean PDC [range]: 0.90 [0.62–1.00]). Compared with AYAs exhibiting prior consistently high adherence trajectories, those with recent start (HR, [95% CI] 1.96, [1.46–2.63]) and gradually increasing (HR, [95% CI] 1.52, [1.20–1.93]) trajectories experienced about 2 times the higher risk of antidepressant discontinuation over the year following cancer diagnosis.
Conclusion
Past antidepressant trajectory is associated with antidepressant discontinuation after AYA cancer diagnosis. Attention is needed in the psycho‐oncologic care of AYAs who recently started antidepressants before cancer diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
ORCID-Profile: Susan dosReis, Wendy Camelo Castillo
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- Institute for Clinical and Translational Research, University of Maryland, Baltimore
Zitieren
APA
Onasanya, O., Damachi, U., dosReis, S., & Camelo Castillo, W. (2025). Antidepressant Use Trajectories and Risk of Discontinuation After Adolescents and Young Adult Cancer Diagnosis. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70131
Vancouver
Onasanya O, Damachi U, dosReis S, Camelo Castillo W. Antidepressant Use Trajectories and Risk of Discontinuation After Adolescents and Young Adult Cancer Diagnosis. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70131
BibTeX
@article{Onasanya2025,
author = {Onasanya, Oluwadamilola and Damachi, Udim and dosReis, Susan and Camelo Castillo, Wendy},
title = {Antidepressant Use Trajectories and Risk of Discontinuation After Adolescents and Young Adult Cancer Diagnosis},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70131}
}
EUVIMED